Literature DB >> 2550047

Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations.

M Dryjski1, D E Schneider, P Mojaverian, B S Kuo, T D Bjornsson.   

Abstract

This study investigated the absorption of low molecular weight heparin (LMWH) after oral administration in man. Six healthy subjects received 5,000 anti-Xa units of LMWH (Kabi 2165) by both i.v. and oral administration. The oral formulations were prepared in pH 4.0 and pH 7.0 buffered solutions. Multiple blood samples were collected after each dose for measurements of anti-Xa, anti-IIa and APTT plasma heparin activities. Pharmacokinetic parameters based on the anti-Xa activity measurements after the i.v. dose were as follows (mean +/- s.d.): t1/2, 1.82 +/- 0.23 h; V, 4.34 +/- 0.651; and CL, 28.0 +/- 6.2 ml min-1. Half-life values based on the anti-IIa and APTT activities were 1.63 +/- 0.43 and 1.09 +/- 0.51 h, respectively. Considerable prolongations in APTT were observed, with APTT at 30 min averaging 55.7 +/- 4.1 s (1.84 +/- 0.27 times baseline values). After oral administration, no measurable plasma heparin activities were observed with either LMWH preparation. The results of this investigation indicate that LMWH does not have detectable plasma activity after oral administration, and that after i.v. administration it has significant anti-IIa and APTT activities in addition to its anti-Xa activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550047      PMCID: PMC1379904          DOI: 10.1111/j.1365-2125.1989.tb05415.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Absorption of heparin from the intestine.

Authors:  T A LOOMIS
Journal:  Proc Soc Exp Biol Med       Date:  1959-07

2.  Gastro-intestinal absorption of heparin and synthetic heparinoids.

Authors:  E WINDSOR; G E CRONHEIM
Journal:  Nature       Date:  1961-04-15       Impact factor: 49.962

3.  Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration.

Authors:  L O Andersson; T W Barrowcliffe; E Holmer; E A Johnson; G E Sims
Journal:  Thromb Res       Date:  1976-12       Impact factor: 3.944

4.  THE USE OF HEPARIN IN THROMBOSIS.

Authors:  G D Murray; C H Best
Journal:  Ann Surg       Date:  1938-08       Impact factor: 12.969

5.  Oral heparin results in the appearance of heparin fragments in the plasma of rats.

Authors:  A K Larsen; D P Lund; R Langer; J Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

6.  Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers.

Authors:  G Bratt; E Törnebohm; L Widlund; D Lockner
Journal:  Thromb Res       Date:  1986-06-01       Impact factor: 3.944

7.  Intestinal absorption of stable heparinic acid complexes.

Authors:  T Y Koh; K R Bharucha
Journal:  J Lab Clin Med       Date:  1972-07

8.  [Duodenal absorption of a low molecular weight heparin in rabbits].

Authors:  C Doutremépuich; A Masse; C Oca; M O Maury; J L Gestreau; F Toulemonde; J C Lormeau
Journal:  Pathol Biol (Paris)       Date:  1984-01

9.  Heparin kinetics determined by three assay methods.

Authors:  T D Bjornsson; K M Wolfram; B B Kitchell
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

10.  A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.

Authors:  G Bratt; E Törnebohm; D Lockner; K Bergström
Journal:  Thromb Haemost       Date:  1985-04-22       Impact factor: 5.249

View more
  6 in total

Review 1.  The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins.

Authors:  Nusrat A Motlekar; Bi-Botti C Youan
Journal:  J Control Release       Date:  2006-06-14       Impact factor: 9.776

2.  Excretion of low molecular weight heparin in human milk.

Authors:  C Richter; J Sitzmann; P Lang; H Weitzel; A Huch; R Huch
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

Review 3.  Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.

Authors:  C J Dunn; B Jarvis
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 4.  Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  C J Dunn; E M Sorkin
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

5.  Movement of heparins across rat gastric mucosa is dependent on molecular weight and pH.

Authors:  Bita Moazed; Linda M Hiebert
Journal:  Pharm Res       Date:  2008-10-21       Impact factor: 4.200

6.  Enhanced antithrombotic effects of unfractionated heparin in rats after repeated oral doses and its relationship to endothelial heparin concentration.

Authors:  L M Hiebert; T Ping; S M Wice
Journal:  Br J Pharmacol       Date:  2008-02-11       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.